Seelos therapeutics doses first patient in a registrational phase ii/iii study of sls-005 in spinocerebellar ataxia

Seelos will also present at the international congress for ataxia research in november    new york , oct. 25, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in a registrational phase ii/iii study of sls-005 (trehalose injection, 90.5 mg/ml for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (sca3, also known as machado-joseph disease) and also announced that it will participate in the international congress for ataxia research (icar) in dallas, texas november 1 st – 4th, 2022.   dr. david biondi, do, faan, from seelos will present: autophagy as a potential treatment pathway in spinocerebellar ataxia: sls-005 (trehalose injection, 90.5 mg/ml for intravenous infusion) at icar on thursday, november 3 rd at 4:45pm ct.
SEEL Ratings Summary
SEEL Quant Ranking